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Primary infection with the human oncogenic
Epstein-Barr virus (EBV) can result in infectious
mononucleosis (IM), a self-limiting disease caused
by massive lymphocyte expansion that predisposes
for the development of distinct EBV-associated
lymphomas. Why some individuals experience this
symptomatic primary EBV infection, whereas the
majority acquires the virus asymptomatically, re-
mains unclear. Using a mouse model with reconsti-
tuted human immune system components, we show
that depletion of human natural killer (NK) cells
enhances IM symptoms and promotes EBV-asso-
ciated tumorigenesis mainly because of a loss of
immune control over lytic EBV infection. These
data suggest that failure of innate immune control
by human NK cells augments symptomatic lytic
EBV infection, which drives lymphocyte expansion
and predisposes for EBV-associated malignancies.INTRODUCTION
Epstein-Barr virus (EBV) is carried as a persistent infection by
more than 90% of the human adult population (Young and Rick-
inson, 2004). Whereas most individuals acquire the virus asymp-
tomatically, up to 10% develop infectious mononucleosis (IM),
especially when primary infection is delayed into adolescence
(Balfour et al., 2013; Kutok and Wang, 2006; Luzuriaga and Sul-
livan, 2010). This disease is accompanied by high EBV titers and
massive lymphocytosis, primarily by EBV-specific CD8+ T cells
targeting viral antigens that are involved in infectious particleCell Reproduction, called lytic infection (Hislop et al., 2007; Odumade
et al., 2012). During the first 5 years after resolution of IM symp-
toms an increased risk to develop EBV-associated classical
Hodgkin lymphoma is observed (Hjalgrim et al., 2003). EBV
viremia, possibly driving EBV-specific CD8+ T cell expansion
and tumorigenesis, could result from insufficient innate immune
control of EBV, and indeed frequencies or counts for the innate
lymphocytes natural killer (NK) cells were found to either
inversely or directly correlate with EBV titers in infectious mono-
nucleosis (Balfour et al., 2013; Williams et al., 2005). Further
arguing for a role of NK cells in EBV-specific immune control, pri-
mary immunodeficiencies that affect NK cells or NK cell recogni-
tion of EBV-transformed B cells have been reported to be asso-
ciated with EBV-positive malignancies and high susceptibility to
EBV (Eidenschenk et al., 2006; Parolini et al., 2000; Shaw et al.,
2012). Because experimental in vivo models for dissecting the
pathogenesis of this human B cell tropic herpes virus or close
relatives are rare (Melkus et al., 2006; Sashihara et al., 2011;
Traggiai et al., 2004; Yajima et al., 2008), addressing and manip-
ulating specific parameters of the immune response to EBV
remained difficult. In order to characterize the role of NK cells
during primary EBV infection, we investigated NOD-scid gc
/
mice with reconstituted human immune system components
(huNSG mice), which constitute a suitable in vivo model for
human NK cell responses and EBV infection as well as virus-
specific immune control (Ra¨mer et al., 2011; Shultz et al., 2010;
Strowig et al., 2009, 2010; White et al., 2012; Yajima et al., 2009).
RESULTS
Human NK Cells Dampen Immunophenotype
during EBV Infection
Human andmouse NK cells specifically express NKp46 (Pessino
et al., 1998; Walzer et al., 2007), and the majority of human NKports 5, 1489–1498, December 26, 2013 ª2013 The Authors 1489
cells of huNSGmice are positive for NKp46 aswell (Strowig et al.,
2010). Therefore, the NKp46-specific monoclonal antibody
BAB281 was used for NK cell depletion. This treatment signifi-
cantly diminished both CD3NKp46+ and CD3CD56+ cell
populations in treated mice (Figures S1A and S1B), whereas an
isotype control antibody neither altered the composition of the
reconstituted human immune system compartments nor the
course of infection (data not shown). Infection of huNSG mice
via intraperitoneal inoculation with 1 3 105 Raji-infecting units
(RIU) of B95-8 EBV resulted in increased CD8+ T cells fre-
quencies and total numbers in both spleen and blood over the
6-week course of infection (Figures 1A–1D). This characteristic
feature of acute IM was significantly more pronounced in NK-
cell-depleted animals (Figures 1A–1D) and was accompanied
with nearly 10-fold elevated serum levels of IFN-g (Figure 1E).
Moreover, in animals depleted of human NK cells, IFN-g
mRNA expressed in CD4+ T cells was also significantly
increased, reaching expression similar to CD8+ T cells in
nondepleted animals after infection (Figures 1F and 1G). The
splenomegaly, resulting from EBV-stimulated CD8+ T cell
expansion, was enhanced in the absence of NK cells (Figure 1H).
Thus, prominent features of symptomatic primary EBV infection
in humans, i.e., acute IM, can bemodeled in huNSGmice and are
strongly pronounced in animals depleted of human NK cells.
Human CD8+ T Cells Display an Activated Memory
Phenotype after EBV Infection
In order to characterize the IM-like T cell expansion after EBV
infection of NK-cell-depleted huNSG mice further, we pheno-
typed their CD4+ and CD8+ T cells. Activated memory T cells
weremainly foundwithin theCD8+ T cell compartment in infected
animals (Figures S2A andS2B) and expanded at the cost of naive
CD8+ T cell frequencies with NK cell depletion significantly
affecting CX3CR1 upregulation and expansion of CD11a+
CD127 CD8+ T cells, which in mice have been proposed to be
short-lived effector cells (Kaech et al., 2003) (Figures S2C and
S2D). Inhibitory receptors and terminal differentiation markers
on CD8+ T cells were also significantly upregulated upon EBV
infection, exclusively on cells coexpressing the memory marker
CD45RO (Figure S2E). Still CD8+ T cells displayed high levels
of the effector molecules perforin and granzyme B with the latter
significantly more expressed in animals depleted of NK cells
(Figure S2F). Despite this terminal differentiation phenotype of
CD8+ T cells during EBV infection of NK-cell-depleted mice,
these CD8+ T cells were still able to exert considerable control
over viral titers in NK-cell-depleted animals, because CD8+
T cell depletion on top of NK cell depletion led to one log
increased viral loads in blood and spleen (Figures 1I and 1J; for
depletion efficiency, see Figures S1C and S1D). Thus, a highly
activated, but still protective, CD8+ T cell phenotype that mimics
the one seen in IM in humans (Hislop and Sabbah, 2008;
Odumade et al., 2012) could be observed during EBV infection
in huNSG mice, especially after human NK cell depletion.
EBV Infection Drives an Initial Expansion of the Human
NK Cell Compartment
This NK-cell-mediated restriction of CD8+ T cell expansion was
associated with the accumulation of a distinct NK cell subset1490 Cell Reports 5, 1489–1498, December 26, 2013 ª2013 The Autin peripheral blood. We observed on average 2-fold increased
frequencies of NK cells (identified as CD3NKp46+ cells unless
otherwise stated) 4 weeks postinfection (Figures 2B and S3A),
coinciding with increased CD16 expression on NK cells (Figure 2
C). This NK cell expansion or enhanced recruitment to the blood
was followed by a contraction of NK cell frequencies in both
the periphery and spleen (Figures 2A, 2B, and S3A). Human
NK cells 6 weeks postinfection did not significantly proliferate
as indicated by staining for the proliferation marker Ki-67 (Fig-
ure S3B) as has been described for NK cells in human acute
IM (Zhang et al., 2007) and only slightly upregulated the activa-
tion marker CD69 (Figure 2E) compared to the robust upregula-
tion for both CD69 and Ki-67 on human CD8+ T cells (Figures 2E
and S3B, respectively). Frequencies of more differentiated
CD16+ NK cells were still elevated (Figure 2D), but the majority
remained NKG2A positive and killer immunoglobulin-like
receptor (KIR) negative (Figures 2E and 2F). Nevertheless, NK
cells expressed less CD27 and a subset upregulated LIR-1
without increased expression of the terminal differentiation
marker CD57 or NKG2C (Figures 2E and 2F; data not shown).
Therefore, EBV infection drives an initial NK cell accumulation
in the blood that precedes the peak of the T cell response
as well as a virus-induced lasting differentiation to mostly
CD16+NKG2A+KIR NK cells, indicative of an early differentia-
tion phenotype.
Human NK Cells Control Viral Load and Prevent
EBV-Induced Malignancy
The functional relevance of this NK cell subset accumulation
became apparent from the analysis of viral titers in animals
depleted of human NK cells. NK cells control EBV infection in
huNSG mice, because cell-associated viral titers in both spleen
and blood were increased one log 5 to 6 weeks postinfection in
the absence of NK cells (Figures 3A and 3B). Infected animals
depleted of NK cells showed a dramatic loss of body weight
(Figure 3C) aswell as a significantly higher incidence of infiltrative
lymphomatous tumors at multiple sites (Figures 3D–3K; Fig-
ure S4A), which were mostly monoclonal (Figures S4B–S4D)
compared to infected nondepleted animals. However, when
NK cells were further expanded and differentiated to express
CD16, KIRs, and CD57 through cytokine-treatment driven
expansion and differentiation, they controlled EBV infection
less well (Figure S5). These data indicate that especially human
NK cells with an early differentiation phenotype control viral
load and prevent detrimental cancerous sequelae of infection
in the host.
Human NK Cells Primarily Respond to Lytic EBV
Infection
Given that, during IM primarily lytic EBV, antigen-specific CD8+
T cells expand (Hislop et al., 2007), the differential regulation of
latent, i.e., cell proliferation inducing, versus lytic viral replica-
tion by NK cells was analyzed. Intriguingly, viral copy numbers
in plasma of NK-cell-depleted animals were more dramatically
increased than in whole blood, up to 100-fold 5 and 6 weeks
postinfection (Figure 4A). This led us to investigate whether
signs of lytic infection were more readily observed in the
absence of NK cells. Indeed, BZLF-1—one of the twohors
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Figure 1. Human NK Cells Curb Human CD8+ T Cell Expansion during EBV Infection
(A–D) Frequency and absolute numbers of CD8+ T cells in spleen (A) and blood (C) 6 weeks after EBV infection in animals with (depl/EBV) and without
(nondepl/EBV) NK cell depletion and in noninfected animals (ctrl). Frequency and absolute number of CD4+ T cells in spleen six 6weeks postinfection (p.i.) (B) and
CD8-CD4 ratio over time p.i. in blood (D, *p < 0.05, two-way ANOVA with Bonferroni correction). CD4+ and CD8+ T cells were identified within live huCD45+CD3+
cells. n = 9–34, mean ± SEM.
(E) Concentration of human IFN-g in serum 6 weeks p.i. in animals with and without NK cell depletion and in noninfected animals (n = 18, mean ± SEM).
(F and G) Relative expression of IFN-g mRNA normalized to 18S in CD4+ T cells (F) and CD8+ T cells (G) sorted from splenocytes of noninfected animals (ctrl),
from animals without (nondepl/EBV), and from animals with NK cell depletion (depl/EBV) 6 weeks after EBV infection. One representative experiment of three
independent experiments is shown. n = 8, mean ± SEM.
(H) Ratio of spleen-to-body weight (BW) 6 weeks p.i. in animals with and without NK cell depletion and in noninfected animals (n = 38, bar represents mean).
Data represent composite data from two to four independent experiments.
(I and J) Viral titers in spleen 6 weeks after EBV infection in animals without depletion (ctrl/EBV), animals depleted of NK cells (NK depl/EBV), and animals depleted
of both NK and CD8+ T cells (NK and CD8 depl/EBV) (I, n = 15, horizontal bar represents geometric mean, two-tailed Mann-Whitney test).
(J) Whole blood at various time points p.i. in animals depleted of both NK and CD8+ T cells (NK & CD8 depl /EBV) and animals depleted of NK cells (NK depl /EBV)
only (n = 10–13 per time point, mean ± SEM, ***p < 0.001, two-way ANOVA with Bonferroni correction). Data represent composite data from two independent
experiments.immediate early transactivators of EBV lytic cycle induction and
indicator of lytic infection—and the late lytic antigen VCA p40
were expressed at increased levels in spleen sections from
NK-cell-depleted animals (Figure 4B). Consistent with a higherCell Reavailability of lytic EBV antigens, splenocytes of NK-cell
depleted and infected animals recognized latently EBV-infected
autologous B cell lines (LCLs) significantly less well by IFN-g
production than nondepleted controls (Figure 4C), and someports 5, 1489–1498, December 26, 2013 ª2013 The Authors 1491
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mice carried slightly elevated CD8+ T cell populations that
stained with MHC class I dextramers carrying lytic EBV antigen
derived peptides (Figure S6). To confirm targeting of lytic infec-
tion by NK cells in vitro, we used AKBM cells that can be
induced to enter the lytic cycle (Figure 4D). As reported, lytic
AKBM cells showed decreased expression of MHC class I mol-
ecules (Pappworth et al., 2007) (Figure 4E) and as a surrogate
for cytotoxicity elicited more degranulation of NK cells derived
from EBV-infected animals than from latent AKBM cells (Fig-
ure 4F). This preferential recognition of lytically EBV-replicating
B cells had been previously described for peripheral blood
human NK cells in vitro (Pappworth et al., 2007). Altogether,
these data suggest that NK cells preferentially respond to lyti-
cally infected cells, and one reason for this might be loss of
inhibitory signals delivered by MHC class I molecules on the
target cells.
Latent EBV Infection Is Unaffected by Human NK Cells
To test our hypothesis that NK cell preferentially restrict lytic
EBV infection in vivo, we infected animals with 1 3 105 RIU
BZLF-1 knockout (KO) B95-8 virus, which is unable to switch
to lytic replication and therefore can only establish the default
program of latent EBV infection. Indeed, no significant weight
loss or difference in tumor formation was observed after KO
virus infection, regardless of the presence or absence of NK
cells (Figures 5A and 5B). Viral titers in spleen (Figure 5C)
and whole blood (Figure 5D) were not significantly affected
by NK cell depletion 6 weeks postinfection. In contrast, a
revertant virus, in which BZLF-1 was reinserted into the
BZLF-1 KO EBV, replicated to higher blood and splenic viral
titers in the absence of NK cells (Figure S7), and therefore
behaved similar to the wild-type virus infection. Interestingly,
immunoactivation of the T cell compartment and development
of splenomegaly after BZLF-1 KO EBV infection was almost
similar to wild-type EBV infection for both NK-cell-depleted
and nondepleted animals (Figure S8), confirming the potency
of the KO virus. However, whereas a significant reduction of
NK cells 6 weeks postinfection could still be observed in blood
(Figures S9A and S9B), KO virus infection neither induced
peripheral NK cell accumulation 4 weeks postinfection (Fig-
ure S9B), nor did it elicit increases in differentiated CD16+
NK cells (Figures S9C and S9D). These results indicate an
absence of protective NK cell responses to latent infection
in vivo and establish lytic infection as the main stimulus for
NK cell accumulation and differentiation.Figure 2. EBV Infection Drives an Initial Expansion and an Early Differe
(A) Frequency and number of splenic NK cells 6 weeks after EBV infection in
noninfected animals (ctrl), respectively, with representative plots. n = 22, mean ±
(B) Frequency of peripheral NK cells in nondepleted animals at day zero, day 28
(C) Expression of CD16 on peripheral NK cells in nondepleted EBV-infected anim
pregated NK cells.
(D) Frequency of CD16+ NK cells in blood and spleen 6 weeks p.i. in nondeplete
(E and F) Expression of CD69 on splenic CD8+ T cells and splenic NK cells, respe
representative staining for NKG2A versus CD69 on pregated splenic NK cells 6 w
representative staining for CD56 versus KIR on pregated peripheral NK cells and f
NK cells were identified as CD3NKp46+ cells within live huCD45+ cells. n = 9–1
experiments.
Cell ReDISCUSSION
Our study suggests that loss of NK-cell-mediated immune con-
trol over lytic EBV infection allows this human tumor virus to
replicate to higher titers, driving lymphocytosis and promoting
predisposition for EBV-associated lymphoma development.
These are IM-like symptoms and known sequelae of IM (Hjalgrim
et al., 2003), and the monoclonality of the emerging tumors as
well as the associated weight loss argue for manifestations of
fatal IM (Brown et al., 1986; Wick et al., 2002). NK cells might
act only late during the course of infection in our model, because
EBV first establishes default latent infection of B cells after
intraperitoneal injection. Lytic replication is then only later reac-
tivated from this latent pool to produce virus particles for
increased B cell transformation and/or conditioning of the
microenvironment for tumor growth (Hong et al., 2005; Ma
et al., 2011). Only this delayed lytic replication seems to be
restricted by human NK cells in huNSG mice. Such continuous
contributions of NK cell responses to viral immune control, in
addition to their role during early immune restriction of viruses,
have also been suggested to form the basis for the selective
NK cell subset expansions, seen during hantavirus, human
immunodeficiency virus (HIV), chikungunya virus, and human
cytomegalovirus (HCMV) infections (Bjo¨rkstro¨m et al., 2011;
Guma´ et al., 2004; Hong et al., 2010; Lopez-Verge`s et al.,
2011; Petitdemange et al., 2011). These expansions might result
from restimulation of NK cells with immunological memory fea-
tures (Paust et al., 2010; Sun et al., 2009) or from recruitment
of NK cell subsets to immune responses by memory CD4+
T cells (Bihl et al., 2010; Horowitz et al., 2010). Our data support
such a prolonged immune control by NK cells during viral infec-
tions and suggest that human NK cells of an early differentiation
phenotype selectively restrict lytic EBV replication.
Instead of CD8+ T cell expansion by elevated viral titers,
caused by uncontrolled lytic replication, human T cell expansion
could, however, also result from loss of direct NK cell cytotoxicity
toward activated T cells, as has been suggested in mice (Lang
et al., 2012; Waggoner et al., 2012). In favor of this interpretation,
we also observed T cell expansion— albeit weaker—upon
BZLF-1 knockout virus infection in NK-cell-depleted huNSG
mice, without significant changes in EBV viremia. Therefore,
NK cells might be involved in the prevention of IM by limiting viral
antigen load that would otherwise drivemassive T cell expansion
and by restricting antiviral T cell expansion directly via cytotoxic
restriction of activated T cells—in a possibly perforin-dependentntiation Phenotype of Human NK Cells
animals with (depl/EBV) and without (nondepl/EBV) NK cell depletion and in
SEM.
p.i., day 42 p.i., and noninfected animals, respectively (n = 27, mean ± SEM).
als at day zero and day 28 p.i. (n = 10), with representative staining for CD16 on
d animals (n = 9, mean ± SEM, one representative experiment for spleen).
ctively, and frequency of LIR-1+ and NKG2A+ splenic NK cells 6 weeks p.i. with
eeks p.i. (E). Frequency of KIR+ and CD27+ NK cells in peripheral blood with
requency of CD57+ peripheral CD8+ T or NK cells, respectively, 6 weeks p.i. (F).
7, mean ± SEM. Data represent composite data from two to four independent
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Figure 3. NK-Cell-Depleted Animals Develop Increased Viral Titers and Tumor Burden after EBV Infection
(A and B) Viral titers in spleen 6 weeks after EBV infection in animals with (depl/EBV) and without (nondepl/EBV) NK cell depletion (A, n = 24, horizontal
bar represents geometric mean, two-tailed Mann-Whitney test) and whole blood at various time points p.i. (B, n = 21–26 per time point, mean ± SEM, **p < 0.01,
***p < 0.001, two-way ANOVA with Bonferroni correction).
(C) Percent body weight loss after EBV infection in animals with and without NK cell depletion at various time points p.i. relative to day 0 (n = 15–26 per time point,
mean ± SEM, ***p < 0.001, two-way ANOVA with Bonferroni correction).
(D) Incidence of all infiltrative tumors at multiple sites 6 weeks p.i. in animals with and without NK cell depletion (n = 36, Fisher’s exact test for actual numbers). All
data represent composite data from three to four independent experiments.
(E) Spleenwith andwithout tumor formation fromNK-cell-depleted or nondepleted animals 6weeks p.i., respectively (left picture), and liver fromNK-cell-depleted
animal with multiple tumors (right picture).
(F–K) Tumor morphology.
(F–H) Pleomorphic immunoblasts, including occasional Reed-Sternberg like-cells (hematoxylin and eosin staining) (F) and (G), pleomorphic immunoblasts
showing CD30 expression.
(legend continued on next page)
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manner—as has been previously reported (Lang et al., 2012;
Waggoner et al., 2012). These two scenarios do not need to be
mutually exclusive but might indeed complement each other.
Altogether, these data suggest that low NK cell reactivity—as
shown for the association with increased cancer risk (Imai
et al., 2000)—might identify EBV seronegative individuals at risk
to develop IM, for which EBV vaccination could be developed.
EXPERIMENTAL PROCEDURES
Mice
NOD/LtSz-scid IL2Rgnull (NOD-scid gc
/ or NSG) and HLA-A2 transgenic
NSG (NSG-A2) mice were obtained from the Jackson Laboratory and bred
and maintained at the Institute of Experimental Immunology, University of
Zu¨rich, under specific pathogen-free conditions. Newborn NSG mice (1 to
5 days old) were irradiated with 1 Gy using a Cs source. Five to six hours after
irradiation, mice were injected intrahepatically with 1–2 3 105 CD34+ human
hematopoietic progenitor cells derived from human fetal liver tissue obtained
from Advanced Bioscience Resources. Preparation of human fetal liver
tissue and isolation of human CD34+ cells was done as described previously
(Strowig et al., 2009, 2010; White et al., 2012). Reconstitution of human
immune system components inmice (huNSG) was analyzed 10–12weeks after
engraftment and again just before the start of the experiments. Mice with more
than 60% reconstitution of huCD45+ human immune system components in
the lymphocytes of peripheral blood were used in the described experiments
(average 85% huCD45+ cells of peripheral blood lymphocytes, 30% CD3+
T cells of human lymphocytes, 60% CD19+ B cells of human lymphocytes,
3% NK cells of human lymphocytes, 80% CD4+, and 20% CD8+ T cells of
human T cells), were of the NSG strain unless otherwise stated, were sex
matched, and were 12–18 weeks old at the start of the experiments. All animal
protocols were approved by the cantonal veterinary office of the canton
of Zu¨rich, Switzerland (protocol nos. 116/2008 and 148/2011). All studies
involving human samples were reviewed and approved by the cantonal ethical
committee of Zu¨rich, Switzerland (protocol no. KEK-StV-Nr.19/08).
Virus Infection and NK and CD8+ T Cell Depletion
GFP-Epstein-Barr virus (EBV) B95-8 wild-type, BZLF-1 KO, and BZLF-1 KO
revertant were produced in 293 cells. Titration of viral concentrates was
done on Raji cells in serial dilutions and calculated as Raji-infecting units
(RIU) using flow cytometric analysis of GFP-positive Raji cells 2 days
after infection of cells. HuNSG mice were infected via intraperitoneal injection
of 13 105 RIUswith the respective viruses and followed for 6 weeks. Depletion
of NK cells in huNSG mice was done via intraperitoneal injection of purified
anti-NKp46 (clone BAB281) in PBS on three consecutive days (total of
300 mg per mouse). On the following day, depletion efficiency was determined
in peripheral blood by flow cytometry (Figures S1A and S1B), and animals were
infected by inoculation via intraperitoneal injection of 1 3 105 RIU EBV. CD8+
T cells were depleted with purified anti-CD8 (clone OKT-8, Bio X Cell) diluted in
PBS via intraperitoneal injection on three consecutive days (total of 150 mg
per mouse) before infection and again 2 weeks postinfection every second
day (50 mg per mouse each application).
Flow Cytometry
All fluorescently labeled antibodies were purchased from BD Biosciences,
BioLegend, Invitrogen, and R&D Systems. Spleens were mechanically disrup-
ted and filtered through a 70 mmcell strainer before separation of mononuclear
cells on Ficoll-Paque gradients. Lysis of erythrocytes in whole blood was
done with NH4Cl. Dextramer staining was performed in accordance with the
manufacturer’s instructions (Immudex). For intracellular staining, the Cytofix/(H) EBV-infected cells with expression of LMP1. Original magnification, 4003.
(I and J) EBNA1+ (brown nuclear staining) pleomorphic immunoblasts in tumor be
and pancreatic tumor (J, black stars indicate the pancreatic acini). Original magn
(K) Spleen infiltrated by large numbers of granzyme B+ cells (original magnificatio
Cell ReCytoperm Kit from BD Biosciences was used. Cell suspensions were stained
with antibodies for 30 min on ice, washed, and analyzed on FACSCanto or
LSR Fortessa cytometers (BD Biosciences). Analysis of flow cytometric data
was performed with FlowJo (Tree Star).
Quantification of Viral Load
Total DNA from whole blood or plasma was extracted using the QIAmp Mini
Kit (Qiagen) in accordance with the manufacturer’s instructions. Splenic tissue
(5–15 mg) was processed using the QIAmp Tissue Kit (Qiagen) in accordance
with the manufacturer’s protocol. DNA was eluted in 50 ml Tris-EDTA and
stored at 4C. Quantitative analysis of EBV DNA was performed by a TaqMan
(Applied Biosystems) real-time PCR technique as described previously
(Berger et al., 2001) with modified primers for the BamHI W fragment (50-
CTTCTCAGTCCAGCGCGTTT-30 and 50-TCTAGGGAGGGGGACCACTG-30)
and the fluorogenic probe (50-(FAM)-CGTAAGCCAGACAGCAGCCAATTGT
CAG-(TAMRA)-30). All PCRs were run on an ABI Prism 7700 Sequence Detec-
tor (Applied Biosystems) and samples analyzed in duplicates.
ELISA
Detection of human IFN-g in serum from huNSG mice was performed with a
human IFN-g ELISA Kit (Mabtech) in accordance with the manufacturer’s
instructions.
Quantitative Real-Time PCR
Total RNA was extracted using the RNeasy Micro Kit (Qiagen) in accordance
with the manufacturer’s instructions. Complementary DNA was reverse tran-
scribed using the GoScript Reverse Transcription System (Promega). Primers
and probes were predesigned Taqman Gene Expression Assays (Applied
Biosystems, IFN-g: Hs00989291_m1 and 18S: Hs99999901_s1). Real-time
PCR was performed on a CFX384 Touch Real-Time PCR Detection System
(Bio-Rad) machine. All samples were run in triplicates and normalized using
18S expression level.
AKBM Cells and Degranulation Assay
EBV-positive AKBM cells that express GFP upon switch from latent to lytic
EBV replication were induced to enter the lytic cycle after ligation with F(ab)
IgG. BZLF-1 and HLA class I expression was monitored after intracellular
staining for BZLF-1 (BZ-1, Santa Cruz Biotechnology) and surface staining
for HLA-ABC (w6/32), respectively. For the degranulation assay, splenic cell
suspensions and induced (lytic) or noninduced (latent) AKBM cells were cocul-
tured at a ratio of 1:1 for 5 hr with addition of monensin after 1 hr, and NK cells
were then analyzed for expression of the degranulation marker CD107a.
Statistical Analysis
All data were analyzed with a two-tailed Student’s t test unless otherwise
stated. A p value of < 0.05 was considered statistically significant. Statistical
analysis and generation of graphs was performed with Prism software
(GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and nine figures and can be found with this article online at http://dx.doi.org/
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Figure 4. Loss of NK-Cell-Mediated Immune Control Augments Lytic EBV Infection
(A and B) EBV wild-type infection.
(A) EBV genome copies in plasma 5 and 6 weeks p.i. in animals with (depl/EBV) and without (nondepl/EBV) NK cell depletion (n = 11–12, mean ± SEM, two-tailed
Mann-Whitney test).
(B) Staining for BZLF-1 (upper left, original magnification, 2003) and VCA (lower left, original magnification, 4003) in splenic sections from NK-cell-depleted
animals 6 weeks p.i. with quantification of BZLF-1+ cells per mm2 in animals with and without NK cell depletion (upper right) and VCA+ cells per mm2 in animals
with and without NK cell depletion (lower right), n = 23–36, horizontal bars represent median, two-tailed Mann-Whitney test.
(C) Functional assay (IFN-g ELISpot) of ex vivo T cell response 6 weeks p.i. with autologous LCLs as targets and effector CD19+ depleted splenic cells from
animals with and without NK cell depletion (E:T = 5:1). n = 18, horizontal bar represents mean.
(D–F) Induction of lytic phase in AKBM cells and NK cell response. Staining for BZLF-1 in latent and lytic (induced) AKBM cells versus BMRF-1-driven GFP
expression (D).
(E) HLA class I expression in latent and lytic AKBM cells (latent, gray graph; lytic, green graph; white graph, unstained control).
(F) Degranulation of pregated splenic NK cells from infected animals 6 weeks p.i. toward latent and lytic AKBM cells (n = 9, horizontal bar represents mean). All
data represent composite data from at least two independent experiments.
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Figure 5. Latent EBV Infection Is Not Affected by Human NK Cells
(A–D) EBV BZLF-1 KO infection. Body weight loss after EBV BZLF-1 KO
infection in animals with (depl/KO) and without (nondepl/KO) NK cell depletion
at various time points p.i. (A, n = 12, mean ± SEM, two-way ANOVA with
Bonferroni correction).
(B) Tumor incidence 6 weeks after EBV BZLF-1 KO infection in NK-cell-
depleted and nondepleted animals (n = 15, Fisher’s exact test for actual
numbers).
(C and D) Viral titers in spleen 6 weeks p.i. (C, n = 18, horizontal bar represents
geometric mean, two-tailed Mann-Whitney test) and blood at various time
points p.i. (D, n = 12–18, mean ± SEM, *p < 0.05, two-way ANOVA with
Bonferroni correction) in animals with and without NK cell depletion. All data
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SUPPLEMENTAL FIGURE LEGENDS 
 
Figure S1: NKp46 specific antibodies efficiently deplete human NK cells and 
CD8 specific antibodies eliminate CD8+ T cells in addition.  
Human NK cells gated as CD3-NKp46+ - stained with clone 9E2 for NKp46 (a) or CD3-
CD56+ cells (b) in peripheral blood one day after depletion with a total of 300µg anti-
NKp46 (clone BAB281) per animal for three consecutive days compared to control 
animals. Shown is one representative experiment of more than five independent 
experiments. n=15, horizontal bar represents mean. c-d, representative staining of NK 
cells (c, pregated on live huCD45+ splenocytes within lymphocyte gate) and T cells (d, 
pregated on live huCD45+CD3+ splenocytes within lymphocyte gate) in animals 
without depletion (ctrl /EBV), animals depleted of NK cells (NK depl /EBV), animals 
depleted of both NK and CD8+ T cells (NK & CD8 depl /EBV) and animals depleted of 
CD8+ T cells (CD8 depl /EBV), respectively. 
 
Figure S2: Phenotype of human memory T cells after EBV infection.  
a-b, activated memory phenotype (CD45RO+HLA-DR+) splenic CD4+ T cells with 
representative staining (a) or splenic CD8+ T cells with representative staining (b) six 
weeks after EBV infection in animals with (depl /EBV) and without (non-depl /EBV) NK 
cell depletion and in non-infected animals (ctrl), respectively. Shown is one 
representative experiment of more than three independent experiments. n=14, mean 
± s.e.m. c-d, naïve (CD45RA+CD11a-) splenic CD8+ T cells with representative plots 
(c), effector cell phenotype (CD11a+CD127-) CD8+ T cells in spleen and expression of 
CX3CR1 on splenic CD8+ T cells six weeks p.i. with representative staining for CD127 
and CD11a (d). n=9-18, mean ± s.e.m. e, frequency of CD45RO+2B4+, 
CD45RO+KLRG1+ and CD45RO+PD-1+ cells the CD8+ T cell compartment with 
representative staining for CD45RO and PD-1 double positive CD8+ T cells in the 
spleen six weeks after EBV infection, respectively, in animals with (depl /EBV) and 
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without NK cell depletion (non-depl /EBV) and in non-infected animals (ctrl). Shown is 
one representative experiment of two independent experiments. n=9, mean ± s.e.m. f, 
frequency of perforin+ and granzyme B+ splenic CD8+ T cells six weeks p.i. with 
representative staining for granzyme B on pre-gated CD8+ T cells. n=19-23, mean ± 
s.e.m. Data represent composite data from at least two independent experiments. 
 
Figure S3: Peripheral NK cell accumulation peaks after 28 days of EBV 
infection.  
a, kinetics of NK cell frequency and NK cell count per µl (fold difference to non-
infected depicted in brackets) in peripheral blood in EBV infected animals and non-
infected control animals at various time points p.i. (n=10, mean ± s.e.m., *P<0.05, 
**P<0.01, two-way analysis of variance (ANOVA) with Bonferroni correction, one 
representative experiment of more than two independent experiments is shown). b, 
frequency of splenic CD8+ T cells or splenic NK cells expressing Ki-67+ in EBV 
infected animals and non-infected control animals six weeks p.i., respectively. n=9-17, 
mean ± s.e.m. Data represent composite data from two independent experiments. 
 
Figure S4: B cell lymphoproliferations of infected mice express EBV antigens 
and are mostly monoclonal in NK cell-depleted animals.  
a-b, lymphoproliferative infiltration of pancreatic tissue, adrenal gland and liver 
immunostained for CD8, CD20, EBNA2 and virus-encoded RNA (EBER, in situ 
hybridization) in NK cell-depleted animals six weeks p.i. (original magnification, 100x). 
b-d, frequency of monoclonal and oligo-/polyclonal (with respect to immunoglobulin 
heavy chain gene rearrangements) lymphoproliferative lesions in EBV infected 
animals with (depl /EBV) and without NK cell depletion (non-depl /EBV) six weeks p.i. 
(b, n=21, χ2 test for actual numbers) and representative electropherograms with 
monoclonal (left), oligoclonal (middle), skewed polyclonal (right) (c) and healthy 
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human PBMC control polyclonal pattern (d). Data represent composite data from 
samples from five independent experiments. 
 
Figure S5: IL-2 or IL-15 cytokine formulations can boost NK cells in huNSG mice 
but drive terminal differentiation of NK cells.  
a-b, frequency of NK cells in peripheral blood with representative staining (a) and  
frequency and absolute number of NK cells in spleen with fold difference shown in 
brackets (b) of huNSG mice after in vivo treatment with different cytokine formulations. 
n=23-24, mean ± s.e.m. Data represent composite data from two independent 
experiments. c, phenotype of splenic NK cells after in vivo treatment with different 
cytokine formulations with respect to CD16, KIR and CD57 expression, respectively. 
n=12, mean ± s.e.m., shown is one representative experiment of two independent 
experiments. d-e, EBV viral load in IL-2 compound 1 treated EBV infected animals (IL-
2 cp1 /EBV) and mock treated EBV infected animals (non-treated /EBV) in spleen 5 
weeks p.i. (d, n=7, horizontal bar represents geometric mean, two-tailed Mann 
Whitney test) and peripheral blood over time (e, n=7-10 per time point, mean ± s.e.m., 
**P<0.01, two-way analysis of variance (ANOVA) with Bonferroni correction). 
Experiment was terminated at 5 weeks p.i. due to animal loss in treatment group. Data 
from one representative experiment are shown. 
 
Figure S6: Epitope-specific CD8+ T cells are present after EBV infection.  
Representative dextramer staining of pre-gated CD8+ splenic T cells six weeks p.i. in 
huNSG-A2 mice with or without NK cell depletion and in non-infected animals (ctrl) for 
lytic (BRLF1 and BMLF1) and latent (LMP2) epitopes. 
 
Figure S7: Infection with EBV BZLF-1 revertant recapitulates EBV wild-type 
infection.  
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a-b, EBV viral load in spleen (a, horizontal bar represents geometric mean, two-tailed 
Mann Whitney test) and peripheral blood six weeks p.i. (b, horizontal bar represents 
mean) in NK cell-depleted (depl /rev) or non-depleted (non-depl /rev) animals infected 
with EBV BZLF-1 revertant (rev) derived from EBV BZLF-1 KO. n=9. Data from one 
experiment are shown. 
 
Figure S8: Ameliorated CD8+ T cell expansion after EBV BZLF-1 KO infection.  
a-e, EBV BZLF-1 infection in huNSG mice. Frequency of CD8+ T cells and CD8-CD4 
ratio six weeks p.i. in spleen in animals with (depl /KO) and without NK cell depletion 
(non-depl /KO) and in non-infected animals (ctrl) (a) and blood six weeks p.i. and over 
time after EBV BZLF-1 KO infection, respectively, in animals with and without NK cell 
depletion.  (b). n=6-13, mean ± s.e.m. c, concentration of human IFN-γ in serum six 
weeks p.i. in animals with and without NK cell depletion and in non-infected animals 
(n=13, mean ± s.e.m.). d, ratio spleen to body weight (BW) six weeks p.i. in animals 
with and without NK cell depletion and in non-infected animals; n=25, horizontal bar 
represents mean. e, activated memory CD45RO+HLA-DR+ splenic CD4+ T cells and 
splenic CD8+ T cells, respectively, six weeks p.i. in animals with and without NK cell 
depletion and in non-infected animals (n=13, mean ± s.e.m.). All data represent 
composite data from at least two independent experiments. 
 
Figure S9: Human NK cells do not significantly expand after EBV BZLF-1 KO 
infection.  
a, frequency and number of splenic NK cells six weeks after EBV BZLF-1 KO infection 
in animals with (depl /KO) and without NK cell depletion (non-depl /KO) and in non-
infected animals (ctrl). n=13, mean ± s.e.m. b, frequencies of peripheral NK cells day 
zero to day 28 and day zero to day 42, respectively, after EBV BZLF-1 KO infection. 
n=6-7. c-d, frequency of CD16+ NK cells in blood (c) and spleen (d) in non-infected 
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(ctrl) and BZLF-1 KO infected (non-depl /KO) animals six weeks p.i. (n=8-9, mean ± 
s.e.m.). All data represent composite data from two independent experiments. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Histology and immunohistochemistry  
Tissue was fixed in 10% saline buffered formalin and paraffin embedded. For 
immunohistochemistry, mouse and rabbit anti-human monoclonal antibodies (all from 
Dako or Zytomed) were used and 4 µm sections processed using standard 
procedures on a BOND-MAX automated immunohistochemistry system (Leica 
Microsystems) with appropriate positive and negative controls. Antibody against 
EBNA1 (clone 1H4) was a gift from Dr. Kremmer. To identify lytic virus infection, IHC 
with antibodies directed against the BZLF1 immediate early protein (clone BZ1, Santa 
Cruz) and against the EBV p40 protein of the VCA complex (clone OT41, kind gift 
from Prof. J. Middeldorp) was used. EBV infection was determined by in situ 
hybridization (ISH) with digoxigenin-conjugated probes for EBV-encoded RNAs 
(EBER-ISH) (Meyer et al., 2011) or an EBER-1 probe developed with alkaline 
phosphatase on a BOND-MAX automated system. 
As described previously for quantitative evaluation of labeled cells (Barros et 
al., 2012), each tissue core was photographed using AxioCam MRc camera (Zeiss) at 
a 200x magnification. The numbers of labeled cells were determined per 1 mm2 using 
the image analysis software HISTO (Biomas). The markers related to EBV infection 
and immune cells were quantified in the spleen and/or in the peri-pancreatic lymph 
nodes but not in extra-lymphatic tissues. 
In both non-depleted and NK cell-depleted mice, marked proliferation of 
pleomorphic immunoblasts was observed. These immunoblasts were uninucleated, 
binucleated or multinucleated, sometimes resembling Hodgkin and Reed-Sternberg 
cells. These cells were CD79a+, CD20+, Bcl2+, EBER-ISH+, EBNA1+, EBNA2+ and 
LMP1+. Atypical CD30+ cells were frequently observed, but numbers were not different 
between the two groups of animals. In all mice from both groups, liver, pancreas, 
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intestine, kidney, and/or peri-visceral fat showed infiltration of polymorphic EBV+ 
immunoblasts, ranging from focal to diffuse, often associated with necrosis.  
 
Analysis of clonality  
DNA was extracted from 5 µm-sections of paraffin embedded tissue, following strict 
measures for avoiding cross-contamination between samples as described (Stefanoff 
et al., 2003). DNA was quantified using a Nanodrop® spectrophotometer and 
approximately 100 ng of DNA was used for PCR testing. All samples were shown to 
be PCR amplifiable for a human constitutive gene (β-globin) and an EBV specific gene 
(EBNA3C). B-cell clonality was investigated by PCR amplifications of immunoglobulin 
heavy chain (IGH) and light chain (IG kappa) gene rearrangements. T-cell clonality 
was ruled out by PCRs for TCR gamma rearrangements. Samples were assayed by 
multiplex PCR reactions using Biomed-2 FR3, FR2 and JH primers (IGH 
rearrangements) as well as Vk, Jk, Kde and INS primers (IG kappa rearrangements) 
(van Dongen et al., 2003), Cl2Mg 1.5 Mm and 1U Platinum® Taq DNA polymerase 
(Invitrogen). PCR thermal profile consisted of an initial cycle of 95ºC at 5 min, followed 
by 35 cycles of 93ºC 45 sec, 60ºC 45 sec and 72ºC 90 sec. As post-PCR step, 
heteroduplex formation was promoted by denaturing PCR products at 94°C for 5 min 
followed by renaturation at 4ºC for 60 min. Products were electrophoresed in 8% non-
denaturing polyacrylamide gels and silver stained. For fluorescent detection, the same 
procedures were performed, using 6’FAM-labeled JH primers. PCR products (1 µl) 
were mixed with 9.5 µl Hi-Di formamide, and 0.5 µl of LIZ fluorescent internal size 
standard. Electrophoresis was performed in a capillary sequencer 3130XL (Applied 
Biosystems) with POP7 polymer. Analysis was performed with the GeneMapper 
version 4.0 software.  
To determine the clonality of a PCR product, a peak-height ratio was calculated as the 
ratio of peak heights between a ’clonal’ prominent peak and the average of the two 
adjacent peaks. A PCR product was defined as monoclonal in the case of 1–2 sharp 
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peaks yielding a peak-height ratio >2. An oligoclonal pattern was defined as a non-
Gaussian distribution of three or more prominent peaks. Polyclonality was defined in 
the presence of multiple peaks with a Gaussian distribution. Multiple peaks with a non-
Gaussian distribution were classified as skewed polyclonal. All results were confirmed 
in the same sample on two repeated runs.  
 
Cytokine treatment 
Cytokine treatment with IL-2 formulations (compound 1 and compound 2) or IL-15 
complexes was done i.p. with a total of 75000 I.U. over five consecutive days as 
described (Krieg et al., 2010) and analysis one day after the last treatment or infection 
with EBV for IL-2 compound 1.    
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